{
    "clinical_study": {
        "@rank": "121042", 
        "acronym": "XeNa", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule."
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis is that metronomic treatment is more efficient than standard treatment."
        }, 
        "brief_title": "Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Purpose: In an open-label randomized phase II trial, patients with metastatic Human\n      Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant\n      WHO performance status < 3 are randomized to receive either capecitabine (day 1-14) plus\n      vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic\n      (3 days a week)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced or metastatic Human Epidermal Growth Factor Receptor2-Negative\n             breast cancer\n\n          -  WHO performance status < 3\n\n        Exclusion Criteria:\n\n          -  Former treatment with Capecitabine or Vinorelbine\n\n          -  Patients who have received more than one line of chemotherapy for metastatic disease\n\n          -  Brain metastases\n\n          -  Malabsorption syndrome\n\n          -  Abnormal organ function\n\n          -  pregnant or lactating women"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941771", 
            "org_study_id": "EUDRACT nr. 2011-003564-72", 
            "secondary_id": "2011-003564-72"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm B", 
                "description": "Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.", 
                "intervention_name": "Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vinorelbine (Navelbine oral)", 
                    "Capecitabine (Xeloda)"
                ]
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.", 
                "intervention_name": "Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Other Names:", 
                    "Vinorelbine (Navelbine oral)", 
                    "Capecitabine (Xeloda)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Capecitabine", 
                "Antineoplastic Agents", 
                "Vinblastine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Metronomic chemotherapy", 
            "Vinorelbine", 
            "Navelbine", 
            "Capecitabine", 
            "Xeloda", 
            "Antineoplastic Agents"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "contact": {
                "email": "svenlang@rm.dk", 
                "last_name": "Sven Tyge Langkjer, MD, ph.d.", 
                "phone": "+45 7846 9721"
            }, 
            "contact_backup": {
                "email": "chajense@rm.dk", 
                "last_name": "Charlotte B Jensen, study nurse", 
                "phone": "+45 7846 4440"
            }, 
            "facility": {
                "address": {
                    "city": "Aarhus", 
                    "country": "Denmark", 
                    "state": "Aarhus C", 
                    "zip": "8000"
                }, 
                "name": "Department of Oncology, Aarhus University Hospital"
            }, 
            "investigator": {
                "last_name": "Sven T Langkjer, MD, ph.d.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Trial of Capecitabine Plus Oral Vinorelbine Day 1 and 8 vs Metronomic Capecitabine Plus Oral Vinorelbine as Treatment of Metastatic Breast Cancer.", 
        "other_outcome": {
            "description": "Monitoring side effects of treatment assessed up to 60 months.", 
            "measure": "Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Side effects of treatment"
        }, 
        "overall_official": {
            "affiliation": "University hospital of Aarhus", 
            "last_name": "Sven Tyge Langkjer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response evaluation at 3rd and 6th cycle by resist criterias. The number of patients that respond to treatment in percent of the total number of patients treated.", 
            "measure": "Primary endpoint is overall response rate i both arms.", 
            "safety_issue": "No", 
            "time_frame": "up to 60 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941771"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Aarhus", 
            "investigator_full_name": "Sven Langkjer", 
            "investigator_title": "consultant, MD, ph.d.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of days from start of treatment to progression of disease assessed up to 60 months", 
                "measure": "Time to progression.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 month"
            }, 
            {
                "description": "Number of days from start of treatment to death assessed up to 60 months.", 
                "measure": "Overall survival.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 month"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "collaborator": {
                "agency": "Pierre Fabre Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}